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Background: The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first
line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and
activity of a lower dose of bevacizumab in pretreated advanced stage EOC.
Methods: We treated 15 patients, mostly with platinum resistant EOC, who had received a median of four prior
cytotoxic regimens, with bevacizumab 5–7.5 mg/kg q21 days in combination with either carboplatin (n = 8), oral
cyclofosfamide (n = 5) or weekly paclitaxel (n = 2). Bevacizumab was administered until disease progression. Tumor
response was assessed by CA125 and fusion 18 F-FDG PET/contrast enhanced CT.
Results: The median number of bevacizumab cycles was 21 (range 3–59). The median baseline CA125 was 272 U/
ml and decreased to 15.2 U/ml at nadir. Tumor response was 4 complete response (CR) (26.7%) and 7 partial
response (PR) (46.7%) by chemotherapy (CT), with an overall response rate of 73.4% (95% CI, 51.0 – 95.8) according
to Response Evaluation Criteria In Solid Tumors (RECIST), and 6 CR (40%) and 4 PR (26.7%) by PET, for an overall
metabolic response rate of 67% (95%CI, 42.8 – 90.6) according to PET Response Criteria in Solid Tumors (PERCIST).
Median progression free survival (PFS) was 21 months and median overall survival (OS) was 24 months. Grade 3
adverse events related to bevacizumab were hypertension (n = 2), proteinuria (n = 1) and epistaxis (n = 5). Treatment
was delayed in five patients for nasal bleeding or uncontrolled hypertension.
Conclusions: Low-dose bevacizumab and chemotherapy was well tolerated and active in a heavily pretreated
population of advanced EOC. Further studies should assess the activity of low dose bevacizumab in EOC.Introduction
Ovarian cancer is the most lethal gynecologic malignant
tumor in developed countries. It is generally diagnosed
in advanced stage and cytotoxic chemotherapy is only
partially effective. The doublet carboplatin and paclitaxel
has been the standard of care for more than 15 years,
and all attempts to add new agents have so far been
unsuccessful.
Recently new targeted treatments have been explored
in epithelial ovarian cancer (EOC), with angiogenesis
being one of the most studied targets for inhibition of* Correspondence: andrea.decensi@galliera.it
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reproduction in any medium, provided the ortumor growth and metastasis [1,2]. Among these targets,
the vascular endotelial growth factor (VEGF) family con-
sists of seven glycoproteins involved in tumor angiogen-
esis [3]. Overexpression of VEGF is often observed in
solid tumors and has been demostrated in ovarian can-
cer, and a correlation with poor prognosis and increased
risk of metastatic disease has been noted [4,5]. The
VEGF pathways have therefore been regarded as a
promising target to treat EOC [6].
Bevacizumab (AvastinW) is a humanized monoclonal
antibody that target VEGF-A and has been registered for
the treatment of advanced disease of colon, non-small-
cell lung, breast, renal and refractory glioblastoma. A
number of phase-II trials have assessed the activity of
bevacizumab in the treatment of recurrent EOC, withal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resistant disease [9-11]. These trials were followed by
three randomized phase-3 trial in first-line treatment of
EOC: GOG 218, ICON 7 and OCEAN trial [12-14].
Results of these trials have shown significant prolonga-
tion of progression free survival (PFS) with the addition
of bevacizumab to standard doublet chemotherapy, with
ICON 7 showing also a favorable trend in overall sur-
vival (OS), based on which the European Medicines
Agency (EMA) has recently approved its use in EOC on
4th October 2011 [15]. In these randomized trials tox-
icity was not negligible, the most common adverse
events being G3-4 hypertension in 3–14.8%, dose-
limiting proteinuria in 0.8%-4%, hemorrhage and throm-
botic events up to 3%, impaired would healing in 1–3.7%
and gastrointestinal perforation in 0%-1.5% of the
patients [16].
Treatment related toxicity and financial costs repre-
sent an important issue for expensive drugs like bevaci-
zumab. Cohn et al. [17] have recently analyzed the cost
effectiveness of bevacizumab in GOG 218 trial, where
the dose of bevacizumab was 15 mg/kg q21 and con-
cluded that the addition of bevacizumab to the adjuvant
treatment was not cost effective. The maintenance treat-
ment improved PFS, but direct and indirect costs raised
substantially [17]. These considerations, coupled with
the results of ICON 7 trial which showed an improved
PFS in patients receiving bevacizumab 7.5 mg/kg q21,
prompted us to explore the activity of low dose bevaci-
zumab in advanced EOC. Notably, only a few dose-
finding studies [18] in cancer patients have so far been
conducted, mostly with inconclusive findings, so that the
optimal biological dose of bevacizumab in most
advanced neoplasms, including EOC, remains unclear.
In contrast, several dose ranging trials have been con-
ducted in the treatment of macular degeneration, with
equivalent efficacy but fewer toxicity of the lower doses
[19,20]. We explored the activity and safety of 5–7.5 mg/
kg q21 bevacizumab in heavily pretreated patients
mostly with platinum resistant EOC.
Patients and methods
This was a mono-institutional case-series performed
under Institutional Review Board support using an off-
label indication of bevacizumab in heavily pretreated
patients with EOC. Our hospital operating procedure for
off label indication was used to treat such patients
according to the Italian law. Informed consents were
collected and declarations of responsibility was signed
by the Chief of the Unit of Medical Oncology for all
patients entered in this study. Eligibility criteria included
at least three prior treatment lines, presence of measur-
able disease, ECOG performance status 0–1, life expect-
ancy of at least 3 months, adequate bone marrow, renaland liver function. Exclusion criteria included bleeding
or clotting disorders, prior or current significant cardio-
vascular disease, including uncontrolled hypertension.
Treatment consisted of bevacizumab 5 mg/kg q21 in 10
patients and 7.5 mg/kg q21 in 5 patients in combination
with carboplatin AUC2 weekly (n = 2) or AUC5 q21
(n = 6) or oral cyclofosfamide 50 mg/day (n = 5) or
weekly paclitaxel (n = 2). Ten patients with body mass
index (BMI) <25 received 5 mg/kg, whereas five patients
with BMI ≥25 received 7.5 mg/kg. This adjustment was
done to minimize the risk of renal toxicity. The choice
between oral and intravenous CT was based on patient’s
preferences and logistical considerations. The two
patients who receive paclitaxel had developed platinum
intolerance. Bevacizumab was administered until disease
progression or unmanageable adverse event. Dose reduc-
tion of bevacizumab was not permitted but was withheld
for any grade 3 or greater bevacizumab-related toxicity
until recovery to grade 1. Chemotherapy was withheld
and reduced by 20% for grade 4 neutropenia,
thrombocytopenia, grade 3 or greater hepatic toxicities,
grade 2 or greater renal toxicity or other toxicity impact-
ing organ function. The use of granulocyte colony
stimulating factors and erytrocyte stimulating factors
was at physician discretion.
Data extracts included demographics, baseline clinical
data, adverse events, and response to treatment. Safety
was evaluated with tests to detect known toxicities of
bevacizumab as high blood pressure, proteinuria by
urinary protein monitoring and close monitoring of GI
toxicity. The NCI CTCAEv4.0 criteria were used.
Each patient underwent integrated 18 F-FDG PET/
Contrast enhanced (Ce)CT before starting the study,
every 3 months and when disease progression was sus-
pected by increasing levels of CA125. 18 F-FDG PET/CT
and CeCT were acquired at the same time using the
same dedicated PET/CT scanner (Discovery LS, GE
Medical Systems, Milwaukee, WI, USA) and the inte-
grated 18 F-FDG PET/CeCT protocol was standardized
as previously described [21].
Briefly, a conventional whole-body PET/CT was per-
formed with 50' after injection of 370 MBq of 18 F-FDG;
colon distension was performed inflating 2 L of room air
during intestinal pharmacological hypotonization (20 mg
of endovenous Joscine bromide), followed immediately
by abdominal PET acquisition. Finally, a CeCT of the ab-
domen (120 KV, 350 mAs, 0.5 s rotation tube), was per-
formed during the portal phase, after injection of i.v.
iodinate contrast medium (Iopamidol 370 mg/I 100 ml;
dose of 1.5 cc/kg of patient weight, injected mechanic-
ally at 3 ml/s). 18 F-FDG-PET/CT, CeCT and 18 F-FDG-
PET CeCT studies were interpreted blindly by two nu-
clear medicine physicians and one radiologist on Advan-
tage Workstation (AW4.2, General Electric Medical
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and MDCT multiplanar reconstructions.
The patients were evaluated for response by Response
Evaluation Criteria In Solid Tumors (RECIST) version
1.1 and PET Response Criteria in Solid Tumors (PER-
CIST) criteria, as recently described [22]. RECIST cri-
teria are typically related to the target lesion dimension,
evaluating treatment response in terms of tumor size. In
particular tumor size is determined by transaxial im-
aging performed most commonly with CT. On the other
hand PERCIST are PET based response criteria related
to the metabolic activity expressed by 18 F-FDG uptake.
In this field standardized uptake value (SUV) and SUL
(SUV corrected for lean body mass) are the most im-
portant parameters able to evaluate treatment response.
According to PERCIST criteria a complete metabolic
response is defined as normalization of all lesions to
SUL less than mean liver SUL; partial metabolic re-
sponse is >30% decrease in SUL peak. (minimum 0.8
unit in SUV decrease); progressive metabolic disease is a
>30% increase in SUL peak (minimum 0.8 unit increase)
or appearance of new lesions or visible increase in extent
of FDG uptake. Stable metabolic disease when all previ-
ous metabolic criteria were not met.
Statistical considerations
As a case series, no specific “a priori” sample size calcu-
lation was performed. Data on 15 patients were deemed
appropriate to provide an initial report on the activity of
low dose bevacizumab in patients with similar clinical
characteristics.
The standard summary statistics for continuous vari-
ables were mean, standard deviation, median, quartiles,
maximum and minimum. The standard summary statis-
tics for discrete variables were count and proportion.
Tolerability and safety were summarized by the appro-
priate standard summary statistics. Confidence intervals
of response rates were adopted as a measure of the vari-
ability of response rate estimates. PFS and OS) were cal-
culated using Kaplan-Meier cumulative survival
estimates defined as the time from the day of study entry
to, respectively, the first day of clinical or metabolic or
radiological progression, and to the day of death from
any cause. In case of no event, times were censored to
the day of last follow-up and follow-up times of patients
dying before progression were censored at the time of
death. All calculations were performed using SPSS ver-
sion 15 and STATA version 11 softwares.
Results
Between October 15, 2007 and June 30, 2011, we treated
15 patients with recurrent stage IIIb-IV EOC. The main
characteristics of the patients are summarized in Table 1.
Briefly, median age was 59 years (range 48–72), medianECOG PS= 1, median BMI 23.1; 13 patients (87%) had
serous epithelial histology and 2 (13%) had endometrioid
histology. The patients received a median number of
four prior cytotoxic regimens (range 3–5). Nine patients
(60%) were platinum resistant defined as progression
within 6 months after completion of the most recent
platinum-based chemotherapy, and six (40%) were par-
tially sensitive. All patients were evaluated for safety and
efficacy on July 2011. The median number of bevacizu-
mab cycles was 21 (range 3–59) and the median follow-
up time was 19 months (range 5–43). The median base-
line CA125 was 272.0 ng/ml and 15.20 ng/ml at nadir.
The waterfall plot of the best Ca125 response in each
subject is illustrated in Figure 1.
Tumor response according to RECIST and PERCIST
criteria is summarized in Table 1. According to RECIST
a complete response (CR) was observed in 4 patients
(26.7%) and a partial response (PR) in 7 patients (46.7%),
with an overall response rate of 73.4% (95% CI, 51.0 –
95.8). According to PERCIST criteria 6 patients (40%)
had a CR and 4 (26.7%) had a PR, with an overall re-
sponse rate of 66.7% (95% CI, 42.8 – 90.6). Four of the
nine platinum resistant patients were treated with carbo-
platin + bevacizumab: three achieved a partial response
and one had a complete response. Two cases of
complete morphological and metabolic response are illu-
strated in Figures 2 and 3.
Median PFS was 21 months (interquartile range, 10–
34) and median OS was 24 months (Figure 4).
The majority of adverse events were mild or moderate
(proteinuria n = 5, hypertension n= 8). Grade 3 adverse
events related to bevacizumab were hypertension (n = 2)
and proteinuria (n = 1). Epistaxis was noted in 5 cases
but no treatment was required. The treatment was never
stopped for toxicity, but was delayed in five patients for
bleeding (n = 2) and uncontrolled hypertension (n = 3).
Seven patients complained of G1 abdominal pain. There
were no cases of bowel perforation or grade 4 toxicity.
Discussion
The standard of care in recurrent, platinum resistant
EOC after three lines of chemotherapy remains unclear
since no chemotherapy agent has ever demonstrated su-
perior activity over another. Topotecan is usually
employed in this setting but a low response rate and its
moderate bone marrow toxicity coupled with the high
costs are a limiting factor [23,24]. Numerous biologic tar-
gets, including VEGF-inhibitors, epidermal growth factor
receptor inhibitors, poly-ADP-ribose polymerase inhibi-
tors, and anti folate agents have recently been studied to
determine their activity in the treatment of EOC [25,26].
Ovarian cancer tumor cells posses VEGF receptors on
their surface suggesting a direct anti-tumor effect in
addition to an anti-angiogenesis effect. Neutralization of
Table 1 Main patient characteristics








CT Response PET Response
01 56 24 Endometroid Resistant III 3 31 Partial Response Partial Response
02 72 19 Serous Partially sensitive IV 3 25 Progression Disease Progression Disease
03 59 25 Endometroid Resistant IV 3 23 Partial Response Complete Response
04 54 23 Serous Resistant IV 4 17 - Complete Response
05 54 21 Serous Partially sensitive IV 5 36 Partial Response Partial Response
06 53 26 Serous Resistant IV 5 53 Complete Response Complete Response
07 48 17 Serous Resistant III 3 26 Partial Response Partial Response
08 56 24 Serous Resistant III 3 9 Complete Response Complete Response
09 70 32 Serous Resistant IV 5 60 Complete Response -
10 61 28 Serous Partially sensitive III 5 68 Partial Response Progression Disease
11 66 26 Serous Resistant III 3 28 Partial Response Complete Response
12 70 20 Serous Partially sensitive III 3 37 Complete Response Complete Response
13 70 20 Serous Resistant III 3 13 Stable Disease Stable Disease
14 49 20 Serous Partially sensitive IV 3 27 Partial Response Partial Response
15 62 22 Serous Resistant IV 4 8 - -
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mation [27,28].
Bevacizumab has shown activity in the treatment of
EOC, with 15-20% response rate and up to 50% PFS at
6 months in phase II clinical trials in advanced EOC [7-
9]. Before routine use of bevacizumab can be recom-
mended in recurrent EOC, however, further analyses of
cost, tolerability and optimal biological dose are neces-
sary. A limited number of studies have evaluated the op-
timal bevacizumab dosage and its correlation with
response rate in different tumors. At variance, several
clinical trials have assessed dose–response relationships
of intravitreal injections of bevacizumab (1.25 mg versusFigure 1 Waterfall plot of best Ca125 response.2.5 mg) for the treatment of diffuse diabetic macular
edema and choroidal neo-vascularization associated with
age-related macular degeneration [19,20]. In these stud-
ies different dosages had similar treatment efficacy, but
intravitreal injection of the highest dose was associated
with higher rate of adverse events.
In a phase I/II dose-escalation trial of bevacizumab in
previously treated metastatic breast cancer the starting
dose of 3 mg/kg every other week was chosen based on
phase I dose-escalation study in solid tumors [18]. Dose
escalation from 3 mg/kg to 20 mg/kg was to occur if no
objective responses were observed among 15 patients.
Although the highest response rate was seen at 10 mg/
Figure 2 Peritoneal metastasis from ovarian cancer close to the ascending colon detected by 18 F-FDG PET/Contrast enhanced (Ce)CT
before starting bevacizumab (A) and at best response (B).
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conclude whether doses higher or lower than 10 mg/kg
were more or less effective.
In the current study we assessed the safety and activity
of low dose bevacizumab, mostly 5 mg/kg q21 days, in
combination with either carboplatin or oral cyclofosfa-
mide or weekly paclitaxel in 15 heavily pre-treated
patients with advanced stage EOC. The treatment
showed to be active, particularly when considering the
lowest 95% confidence limit of tumor response, in a pa-
tient population for whom little therapeutic options are
available. The treatment was well tolerated with low in-
cidence of proteinuria, hypertension, abdominal pain
and bleeding. There were no cases of intestinal perfor-
ation or grade 4 toxicities, and treatment was never
stopped for toxicity.
The addition of low-dose bevacizumab to chemother-
apy was quite active with a best tumor response (CR+
RP) as high as 73.4% by CT scan and 67% by PET. The
attainment of a tumor response by carboplatin rechal-
lange in all four platinum resistant patients is noticeable
and deserves to tested in future studies. Previous studies
have shown significant activity of bevacizumab in plat-
inum resistant disease [9-11]. Median progression-free
survival was 21 months and median overall survival was
24 months, an observation which is in line with the
results obtained by O’Malley et al. with paclitaxel/beva-
cizumab as compared to weekly paclitaxel alone in aFigure 3 Peritoneal carcinomatosis from ovarian cancer detected by 1
bevacizumab (A) and at best response (B).similar population [29]. There was no significant correl-
ation between bevacizumab related adverse events and
response rate or between bevacizuamb dose and re-
sponse rate.
We used 18 F-FDG PET/CeCT colonography to detect
persistence/recurrence of disease and to assess tumor re-
sponse using RECIST and PERCIST criteria. 18 F-FDG
PET/TC is now an essential imaging technique in EOC
monitoring and is clearly superior to CeCT especially to
identify peritoneal deposits and lymph-nodes metastases
[30]. 18 F-FDG PET/TC is also able to asses treatment
response earlier than conventional imaging as CeCT or
MRI and metabolic responders have a longer median
overall survival than non responders [31]. The combined
use of 18 F-FDG PET/CT and CeCT, acquired at the
same time in the same dedicated PET/CT scanner has
been shown to improve the diagnostic accuracy of the
18 F-FDG PET/CT alone [32], especially in case of hostile
anatomy of the abdomen and pelvis after surgery
[32,33]. However one of the major limitation of this
diagnostic tool remains the inability to distinguish small
peritoneal disease from non specific bowel uptake [32].
Thus we combined 18 F-FDG PET/CeCT with colon dis-
tension [21] in order to eliminate aspecific bowel activity
and to discover small peritoneal nodules close to intes-
tinal wall [34,35].
Our study has several limitations, including the small
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Figure 4 Kaplan-Meier progression-free survival (A, top panel) and overall survival (B, bottom panel).
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suggests that the combination of low-dose bevacizumab
and chemotherapy is well tolerated and active in heavily
pretreated patients with advanced EOC. A comparative
trial with conventional chemotherapy is warranted.
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